Cowan HR, Pratt D, Shah JL, Woods SW, Alameda L, Lepage M, Shankman SA, Addington J, Arango C, Bearden CE, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Castillo-Passi RI, Chen EYH, Choi J, Conus P, Corcoran CM, Cornblatt BA, Diaz-Caneja CM, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Gonçalves C, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kahn RS, Kane JM, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Mathalon DH, McGorry PD, Nelson B, Nordentoft M, Pasternak O, Pearlson GD, Perez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Shenton ME, Silverstein SM, Smesny S, Stone WS, Strauss GP, Thompson JL, Upthegrove R, Verma S, Wang J, Wolf DH, Yung A, Zhang T, Crawford C, Yassin W, Kelly S, Coleman M, Jacobs G, Lewandowski KE, Penzel N, Baker J, Cecci G, Allott K, Buccilli K, Tod S, Addamo L, Xu L, Accelerating Medicines Partnership®—Schizophrenia (AMP® SCZ), Mittal VA. Premorbid adjustment problems, negative symptoms, and cognitive impairment in a large international sample at clinical high risk for psychosis: Findings from the Accelerating Medicines Partnership-Schizophrenia. Schizophr Bull. 2025 Dec 05.
